Cervical Cancer Diagnostic Tests Market to Rise Thanks to Benefits Associated with HPV and Pap Co-testing
The cervical cancer diagnostic tests market is expanding at a swift pace owing to the rising number of deaths caused by cervical cancer all around the globe. As per the World Health Organization, cervical cancer is responsible for causing over 270,000 deaths each year, especially in emerging countries. The swift spread of the human papillomavirus in females, the consistent usage of oral contraceptive pills, and weakening immune systems are amongst the key factors driving demand from the cervical cancer diagnostic tests market. This is why diagnostic tests such as Pap smear tests, colposcopy, and HPT testing are used for the early detection of cervical cancer in individuals.
TMR, a market intelligence company, has studied the functioning and credibility of these tests and has thrown light on the various limitations of these tests. As per TMR, the global cervical cancer diagnostic tests market stood at US$5.9 billion in 2013 and is predicted to expand at a CAGR of 6.1% between 2014 and 2020 to reach US$8.9 billion by 2020.
Browse Market Research Report of Cervical Cancer Diagnostic Tests Market: http://www.transparencymarketresearch.com/cervical-cancer-diagnostic-tests-market.html
Is HPV Testing Alone Beneficial for Cervical Cancer Screening?
The Food and Drug Administration, in April 2014, approved the utilization of HPV DNA test as the first-line primary screening test to be utilized on women aged 25 and above. The test helps in the diagnosis of HPV types 18 and 16 and provides pooled results for 12 more high-risk HPV types. This new approval was given after performing clinical trials including over 47,000 women. The trial results demonstrated that the HPV test utilized in the study had a better performance as compared to the Pap smear test in identifying women who are at risk of developing acute cervical cell abnormalities.
What are the Major Benefits of HPV and Pap Co-Testing?
HPV and Pap co-testing is highly advantageous for women aged 30 or older, as this co-testing has a much lower chance of missing an abnormality as compared to Pap testing done alone. Hence, women having a normal Pap and negative HPV test in conjunction have a minimal chance of developing an undetected serious abnormality in the coming years. HPV and Pap co-testing may also enhance the detection of glandular cell abnormalities, such as cancer of glandular cells of the cervix.
Browse Market Research Press Release of Cervical Cancer Diagnostic Tests Market: http://www.transparencymarketresearch.com/pressrelease/cervical-cancer-diagnostic-tests-market.htm
Are There any Limitations Associated with Cervical Cancer Diagnostic Tests?
Though cervical cancer diagnostic tests are very effective, they are not yet fully accurate. There are many limitations on cervical cancer screening owing to the nature of HPV infections. HPV infections are transient in nature and create momentary changes in the cervical cells. This is why regular cervical screening may detect cervical cell changes and HPV infections that may never initiate cancer. Additionally, these tests may present normal cells as abnormal, or vice versa, due to the transience of the condition. These limitations may restrain the usage of cervical cancer diagnostic tests in the forthcoming years.
Becton, Abbott Laboratories, Dickinson and Company, Guided Therapeutics, Hologic, Inc., OncoHealth Corp., Femasys, Inc., Quest Diagnostics, Inc., QIAGEN, Roche Diagnostics, and Zilico Ltd. are amongst the prime players dominant in the market for cervical cancer diagnostic tests.